The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man
Abstract
For more than three decades, acetaminophen (INN, paracetamol) has been claimed to be devoid of significant inhibition of peripheral prostanoids. Meanwhile, attempts to explain its action by inhibition of a central cyclooxygenase (COX)‐3 have been rejected. The fact that acetaminophen acts functionally as a selective COX‐2 inhibitor led us to investigate the hypothesis of whether it works via preferential COX‐2 blockade. Ex vivo COX inhibition and pharma‐cokinetics of acetaminophen were assessed in 5 volunteers receiving single 1000 mg doses orally. Coagulation‐induced thromboxane B 2 and lipopolysaccharide‐induced prostaglandin E 2 were measured ex vivo and in vitro in human whole blood as indices of COX‐1 and COX‐2 activity. In vitro , acetaminophen elicited a 4.4‐fold selectivity toward COX‐2 inhibition (IC 50 = 113.7 μmol/L for COX‐1;IC 50 = 25.8 μmol/L for COX‐2). Following oral administration of the drug, maximal ex vivo inhibitions were 56% (COX‐1) and 83% (COX‐2). Acetaminophen plasma concentrations remained above the in vitro IC 50 for COX‐2 for at least 5 h postadministration. Ex vivo IC 50 values (COX‐1: 105.2 μmol/L; COX‐2: 26.3 μmol/L) of acetaminophen compared favorably with its in vitro IC 50 values. In contrast to previous concepts, acetaminophen inhibited COX‐2 by more than 80%, i.e. , to a degree comparable to nonste‐roidal antiinflammatory drugs (NSAIDs) and selective COX‐2 inhibitors. However, a >95% COX‐1 blockade relevant for suppression of platelet function was not achieved. Our data may explain acetaminophen's analgesic and antiinflammatory action as well as its superior overall gastrointestinal safety profile compared with NSAIDs. In view of its substantial COX‐2 inhibition, recently defined cardiovascular warnings for use of COX‐2 inhibitors should also be considered for acetaminophen.—Hinz, B., Cheremina, O., Brune, K. Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man. FASEB J. 22, 383–390 (2007)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hinz et al. (2007) demonstrated 4.4x more selectivity toward the inhibition of COX-2 (IC 50 = 25.8 µmol/L) over COX-1 (IC 50 = 113.7 µmol/ L) from in vitro assays using whole human blood [51].”
From Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action (2021) · cites this paper as [51]
In the citing paper
“In this study, paracetamol demonstrated over 80% blockade of COX-2 activity comparable to NSAIDs and COX-2 selective inhibitors.”
From Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action (2021) · cites this paper as [51]
In the citing paper
“It is not clear why there are significant discrepancies in relation to inhibition of COX-1 and COX-2 activities by paracetamol as reported by Hinz et al. [51] and Mitchell et al. [33].”
From Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action (2021) · cites this paper as [51]
Citations
Cites
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989 · cited 2×
“Attempts to explain the pharmacological action of acetaminophen as inhibition of a central COX isoform, derived from the same gene as COX-1 and referred to as COX-3 (8), have been meanwhile rejected for several reasons (9).”
BackgroundCyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
The antioxidants of human extracellular fluids
Halliwell, B., & Gutteridge, J. M. C. (1990) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(90)90510-6 · Cited by 1,341 · cited 1×
“Thus, the presence of various enzymatic and nonenzymatic antioxidant components in human plasma (33) may explain why acetaminophen elicited the most pronounced COX-2 inhibition in human whole blood as compared to the two other experimental systems.”
ResultSerhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., & Gronert, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.8.1197 · Cited by 1,189 · cited 1×
“Apart from these factors, evidence for COX-2 inhibition by acetaminophen is also supported by previous findings showing that acetaminophen like indomethacin and aspirin confers the synthesis of 18R-hydroxyeicosapentaenoic acid (HEPE) and 15RHEPE through interaction with the COX-2 enzyme (34).”
ResultLangenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada, P. C., Mahler, J. F., Lee, C. A., Goulding, E. H., Kluckman, K. D., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90126-4 · Cited by 1,123 · cited 1×
“A COXindependent mechanism for the gastrointestinal toxicity of NSAIDs is further supported by findings in COX-1 knockout mice, which still develop gastric erosions in response to oral administration of indomethacin (45).”
BackgroundPharmacological analysis of cyclooxygenase-1 in inflammation
Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., & Isakson, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13313 · Cited by 807 · cited 2×
“A peripheral antiinflammatory action is further supported by findings showing acetaminophen as an inhibitor of nociception and edema in the rat carrageenan footpad model (27, 28), an inflammatory condition critically dependent on COX-2-derived PGs (29).”
BackgroundFLOWER, R. J., & VANE, J. R. (1972) · Nature · doi:10.1038/240410a0 · Cited by 779 · cited 2×
“Whereas the drug was first associated with a predominant suppression of PG synthesis in brain tissue ( 3 ), subsequent studies contradicted a cell-specific modulation (4 –7).”
BackgroundMethodMechanism of Action of Paracetamol
Graham, G. G., & Scott, K. F. (2005) · American Journal of Therapeutics · doi:10.1097/00045391-200501000-00008 · Cited by 648 · cited 4×
“Moreover, it turned out that acetaminophen elicits no measurable inhibition of PG formation in broken cell preparations but a profound suppression in intact cells (7).”
BackgroundInfluentialNonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years
Wallace, J. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9041264 · Cited by 569
Cannon, C. P., Curtis, S. P., FitzGerald, G. A., Krum, H., Kaur, A., Bolognese, J. A., Reicin, A. S., Bombardier, C., Weinblatt, M. E., van der Heijde, D., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69666-9 · Cited by 522 · cited 1×
“PGE2 is the currently most plausible explanation for the cardiovascular hazard conferred by selective and nonselective COX-2 inhibitors (20, 30).”
Background
Research works printed but not linked: 1
- Mantzke U. S., 2002, Paracetamol in childhood. Current state of knowledge and indications for a rational approach to postoperative analgesia, Anaesthesist, 51, 735
Cited by
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
“However the final jury on this question is not out yet (78, 79).”
BackgroundGraham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
“…the highly potent analgesic effects of nonsteroidal anti-inflammatory drugs (NSAIDs) like paracetamol (acetaminophen), a selective COX-2 inhibitor (Hinz et al., 2008), or ibuprofen, a potent inhibitor of 2-AG oxidation by COX-2 (Prusakiewicz et al., 2009) require the activation of CB1 receptors…”
BackgroundNew insights into the use of currently available non-steroidal anti-inflammatory drugs
Brune, & Patrignani, P. (2015) · Journal of Pain Research · doi:10.2147/jpr.s75160 · Cited by 469
“38,39 42 Inhibition of prostanoid biosynthesis by NSAIDs is responsible for the therapeutic activities of these drugs; 11,32 however, this inhibitory activity also suppresses other effects of these prostanoids, resulting in the side effects associated with NSAID treatment.”
Metadata
- Authors
- Hinz, B., Cheremina, O., & Brune, K.
- Affiliations
- University of Rostock (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- ORCID
- Hinz, Burkhard
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-09-20
- Volume
- 22
- Issue
- 2
- Pages
- 383-390
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2132889863
- Cited by
- 478
- References
- 51
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 15 · 2023: 14 · 2022: 19 · 2021: 19 · 2020: 14 · 2019: 28 · 2018: 33 · 2017: 29 · 2016: 35 · 2015: 49 · 2014: 28 · 2013: 33 · 2012: 36
- FWCI
- 15.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- paracetamol, COX-2 inhibition, COX-1 inhibition, COX-2 inhibitors, thromboxane B2, prostaglandin E2, plasma pharmacokinetics, gastrointestinal safety, cardiovascular risk, analgesic mechanism, anti-inflammatory mechanism
- MeSH terms
- Acetaminophen, Cells, Cultured, Humans, Isoenzymes, Monocytes, Time Factors, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man. https://app.cochat.ai/papers/10.1096/fj.07-8506com
- The paper
- Hinz, B., Cheremina, O., & Brune, K. (2008). Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man. The FASEB Journal. https://doi.org/10.1096/fj.07-8506com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.